A man presents with a history of dysuria and urethral discharge after having unprotected sexual intercourse. Gram-staining of the purulent discharge is seen in the following image. What is the treatment of choice for this infection?

Explanation

## Correct Answer: C. Ceftriaxone The clinical presentation of dysuria and purulent urethral discharge following unprotected sexual intercourse is pathognomonic for acute gonorrhea. Gram-staining of urethral discharge in males with gonorrhea classically shows **intracellular gram-negative diplococci** (Neisseria gonorrhoeae) within polymorphonuclear leukocytes. This is the gold standard for presumptive diagnosis in symptomatic males. **Ceftriaxone** is the current gold-standard treatment for gonorrhea in India and globally, as per WHO and Indian STI guidelines. N. gonorrhoeae has developed widespread resistance to penicillins, tetracyclines, fluoroquinolones, and macrolides over the past two decades. Ceftriaxone (500 mg IM single dose or 1 g IM single dose) remains highly effective with minimal resistance rates (<1% in most regions). It achieves excellent urethral and systemic penetration, ensuring cure of both uncomplicated urethritis and potential disseminated infection. The single-dose regimen ensures compliance and is cost-effective in the Indian healthcare setting. Ceftriaxone is also the DOC for gonococcal pharyngitis, proctitis, and conjunctivitis, making it the universal first-line agent for all gonococcal infections. ## Why the other options are wrong **A. Azithromycin** — Although azithromycin was historically used for gonorrhea, resistance rates have escalated dramatically in India (>30% in many centers). WHO and Indian STI guidelines no longer recommend azithromycin as monotherapy for gonorrhea due to treatment failures and emerging resistance. It is no longer a reliable first-line option. **B. Erythromycin** — Erythromycin has poor urethral penetration and high resistance rates in N. gonorrhoeae (>50% in India). It is not recommended for treatment of gonorrhea. Erythromycin is occasionally used for chlamydial co-infection in pregnant women, but never as monotherapy for gonorrhea in non-pregnant patients. **D. Penicillin G** — Penicillin G was the original DOC for gonorrhea but is now obsolete due to widespread chromosomal and plasmid-mediated resistance (>80% resistance in India). Penicillin-resistant N. gonorrhoeae (PRNG) emerged in the 1970s–80s and is now endemic. Using penicillin would result in treatment failure and continued transmission. ## High-Yield Facts - **Gram-negative intracellular diplococci** in PMNs on Gram stain = presumptive diagnosis of gonorrhea in symptomatic males (>95% sensitivity). - **Ceftriaxone 500 mg–1 g IM single dose** is the current WHO and Indian STI guideline DOC for all gonococcal infections (urethritis, pharyngitis, proctitis, conjunctivitis). - **N. gonorrhoeae resistance**: Penicillin (>80%), Tetracycline (>70%), Fluoroquinolones (>50%), Azithromycin (>30%) — all obsolete; Cephalosporins remain <1% resistance. - **Chlamydia co-infection** occurs in 30–50% of gonorrhea cases in India; dual therapy with ceftriaxone + azithromycin or doxycycline is recommended if chlamydia not ruled out. - **Contact tracing and treatment** of sexual partners within 60 days is mandatory under Indian STI guidelines; all partners must receive the same ceftriaxone regimen. ## Mnemonics **CEFT for Gonorrhea** **C**eftriaxone is the **E**ssential **F**irst-line **T**reatment for gonorrhea. Remember: Cephalosporins (3rd generation) are the only remaining reliable class with <1% resistance globally. **OLD drugs FAIL (Gonorrhea Resistance)** **O**bsolete: Penicillin (>80% R), **L**ess effective: Tetracyclines (>70% R), **D**ated: Fluoroquinolones (>50% R) — all fail. Use **CEFT** instead. ## NBE Trap NBE may pair "macrolide" (azithromycin/erythromycin) with "urethritis" to trap students who confuse gonorrhea treatment with chlamydial or non-gonococcal urethritis (NGU). However, in the context of Gram-negative diplococci on Gram stain, cephalosporin is the only correct answer. ## Clinical Pearl In Indian STI clinics, the Gram stain finding of intracellular gram-negative diplococci in a symptomatic male is sufficient to initiate ceftriaxone immediately without waiting for culture confirmation, reducing transmission and treatment delay. Partner notification and treatment within 60 days is critical to break the transmission chain in the community. _Reference: Jawetz, Melnick & Adelberg's Medical Microbiology (Chapter on Neisseria); KD Tripathi Essentials of Medical Pharmacology (Chapter on Antibiotics); Indian STI Management Guidelines (NACO/ICMR)_